This article is more than 5 years old. Information may no longer be current.
BMI affected endocrine therapy efficacy in premenopausal women with breast cancer
Click Here to Manage Email Alerts
Women with breast cancer and an overweight BMI had a significantly higher risk for disease recurrence and death when treated with anastrozole plus goserelin compared with normal weight women. Researchers posited that this increase is likely due to influencing aromatase availability or ovarian suppression.
In the prospective ABCSG-12 trial, researchers compared the efficacy of treatment with goserelin plus anastrozole or tamoxifen with or without zoledronic acid. They enrolled 1,803 premenopausal women with hormone receptor-positive breast cancer. The primary endpoint was DFS. The median follow-up was 62.6 months.
More specific comparisons indicated that an overweight BMI influenced the efficacy of anastrozole with a 60% increased risk for disease recurrence compared with normal weight women (95% CI, 1.06-2.41). Overweight women also had twice the risk for death (HR=2.14; 95% CI 1.17-3.92).
When they compared anastrozole and tamoxifen in just overweight women, the researchers found that those women assigned anstrozole had an increased risk of recurrence (HR=1.49; 95% CI, 0.93-2.38) and an extremely increased risk for death (HR=3.03; 95% CI 1.35-6.82).
“Taken together,” the researchers wrote, “this suggests that BMI may serve as a useful surrogate parameter for total-body aromatization and eventually may be a practical tool to tailor aromatase inhibitor therapy for individual patients.”
For more information:
- Pfeiler G. J Clin Oncol. 2011;doi:10.1200/JCO.2010.33.2585.